

Aleksandr Ianevski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6118740/publications.pdf>

Version: 2024-02-01

46
papers

2,802
citations

279798

23
h-index

265206

42
g-index

59
all docs

59
docs citations

59
times ranked

4934
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated root phenotypes for improved rice performance under low nitrogen availability. <i>Plant, Cell and Environment</i> , 2022, 45, 805-822.	5.7	23
2	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2022, 6, e701.	2.7	4
3	Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. <i>Nature Communications</i> , 2022, 13, 1246.	12.8	163
4	Mono- and combinational drug therapies for global viral pandemic preparedness. <i>IScience</i> , 2022, 25, 104112.	4.1	19
5	SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. <i>Nucleic Acids Research</i> , 2022, 50, W739-W743.	14.5	139
6	DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs). <i>Nucleic Acids Research</i> , 2022, 50, W272-W275.	14.5	15
7	Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells. <i>Methods in Molecular Biology</i> , 2022, 2449, 327-348.	0.9	4
8	RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. <i>Leukemia</i> , 2021, 35, 1087-1099.	7.2	32
9	Safe-in-Man Broad Spectrum Antiviral Agents. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 313-337.	1.6	1
10	Neural signaling modulates metabolism of gastric cancer. <i>IScience</i> , 2021, 24, 102091.	4.1	14
11	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. <i>Science Advances</i> , 2021, 7, .	10.3	28
12	Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS. <i>Blood Cancer Discovery</i> , 2021, 2, 238-249.	5.0	25
13	Computational Drug Repositioning and Experimental Validation of Ivermectin in Treatment of Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 625991.	3.5	7
14	Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	27
15	Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19. <i>Viruses</i> , 2021, 13, 651.	3.3	50
16	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8486-8509.	6.4	28
17	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 14755.	3.3	7
18	Active Components of Commonly Prescribed Medicines Affect Influenza A Virus–Host Cell Interaction: A Pilot Study. <i>Viruses</i> , 2021, 13, 1537.	3.3	3

#	ARTICLE	IF	CITATIONS
19	Nafamostatâ€“Interferon-Î± Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. <i>Viruses</i> , 2021, 13, 1768.	3.3	15
20	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. <i>MBio</i> , 2021, 12, e0334721.	4.1	45
21	Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. <i>Viruses</i> , 2021, 13, 2489.	3.3	20
22	Identification and Tracking of Antiviral Drug Combinations. <i>Viruses</i> , 2020, 12, 1178.	3.3	48
23	Potential Antiviral Options against SARS-CoV-2 Infection. <i>Viruses</i> , 2020, 12, 642.	3.3	92
24	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. <i>Cancers</i> , 2020, 12, 1694.	3.7	13
25	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. <i>PLoS Computational Biology</i> , 2020, 16, e1007604.	3.2	43
26	Discovery and development of safe-in-man broad-spectrum antiviral agents. <i>International Journal of Infectious Diseases</i> , 2020, 93, 268-276.	3.3	169
27	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , 2020, 36, 3602-3604.	4.1	68
28	SynergyFinder 2.0: visual analytics of multi-drug combination synergies. <i>Nucleic Acids Research</i> , 2020, 48, W488-W493.	14.5	545
29	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. <i>Blood</i> , 2020, 135, 597-609.	1.4	134
30	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
31	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
32	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
33	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
34	Common Nodes of Virusâ€“Host Interaction Revealed Through an Integrated Network Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 2186.	4.8	67
35	Novel Antiviral Activities of Obatoclox, Emetine, Niclosamide, Brequinar, and Homoharringtonine. <i>Viruses</i> , 2019, 11, 964.	3.3	68
36	Genome-wide off-targets of drugs: risks and opportunities. <i>Cell Biology and Toxicology</i> , 2019, 35, 485-487.	5.3	16

#	ARTICLE	IF	CITATIONS
37	Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010–2018. <i>Viruses</i> , 2019, 11, 207.	3.3	81
38	Expanding the activity spectrum of antiviral agents. <i>Drug Discovery Today</i> , 2019, 24, 1224-1228.	6.4	31
39	Prediction of drug combination effects with a minimal set of experiments. <i>Nature Machine Intelligence</i> , 2019, 1, 568-577.	16.0	99
40	Novel activities of safe-in-human broad-spectrum antiviral agents. <i>Antiviral Research</i> , 2018, 154, 174-182.	4.1	64
41	Interactive visual analysis of drug–target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing. <i>Briefings in Bioinformatics</i> , 2018, , .	6.5	25
42	A Systems Approach to Study Immuno- and Neuro-Modulatory Properties of Antiviral Agents. <i>Viruses</i> , 2018, 10, 423.	3.3	10
43	Single Passage of Human Metapneumovirus in LLC-MK2 Cells Does Not Affect Viral Protein-Coding Capacity. <i>Genome Announcements</i> , 2018, 6, .	0.8	0
44	SynergyFinder: a web application for analyzing drug combination dose–response matrix data. <i>Bioinformatics</i> , 2017, 33, 2413-2415.	4.1	403
45	Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection <i>in vitro</i> and differentially affect cellular signaling, transcription and metabolism. <i>Antiviral Research</i> , 2017, 139, 117-128.	4.1	88
46	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. <i>Viruses</i> , 2017, 9, 271.	3.3	39